Treatment of pemphigus patients in the COVID-19 era: A specific focus on rituximab

Dermatol Ther. 2020 Nov;33(6):e14188. doi: 10.1111/dth.14188. Epub 2020 Sep 3.

Authors

Hamidreza Mahmoudi¹, Soheil Tavakolpour², Ali Nili¹, Ali Salehi Farid¹, Maryam Daneshpazhooh¹, Mohammad Rashidian²

Affiliations

¹ Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

No abstract available

Publication types

Letter

MeSH terms

B-Lymphocytes / physiology
COVID-19 / epidemiology*
COVID-19 / immunology
Humans
Pemphigus / drug therapy*
Rituximab / adverse effects*
SARS-CoV-2*

Substances

Rituximab